An Opdivo-Yervoy combo yielded a significantly longer treatment-free survival period for patients with previously untreated advanced or metastatic renal cell carcinoma than standard of care sunitinib.
An immunotherapy cocktail from Roche helped slow an aggressive type of breast cancer where new treatments have proven elusive.
Merrimack Pharmaceuticals’ stock plunged more than 32 percent after the company announced the termination of the SHERLOC Phase II clinical trial.
Boston-based Proteostasis Therapeutics announced positive preliminary data from the ongoing Phase I clinical trial of PTI-808 and PTI-801 in cystic fibrosis. Despite being an early-stage trial and preliminary data, company shares exploded upward by 301 percent, with more than 44 million shares trading hands.
Merck & Co.’s cancer drug Keytruda in combination with Pfizer Inc.’s Inlyta met the main goals of a late-stage study for the most common form of kidney cancer.
Eisai Co. and Purdue Pharma L.P. announced top-line results from the companies’ SUNRISE 2 Phase III clinical trial of lemborexant for sleep-wake disorders.
People with restless legs syndrome may be more likely to think about suicide or to actually make plans to take their own lives, compared to people without the condition, a new study suggests.
Drugmakers Sanofi and Regeneron received positive results for Dupixent, which treats eczema and is seen as a key driver of future revenues.
Bristol-Myers Squibb’s blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.
Bristol-Myers Squibb and Israel’s Compugen will collaborate in clinical trials for patients with advanced solid tumors.